Program
Abatacept
Also written as “Belatacept”, “abatacept” and “Abatacept (BMS-188667)”.
Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · Psoriasis · Arthritis, Psoriatic · Lupus Nephritis, led by 3 companies.
Drug pageAbatacept: every studyAll 218 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 652 open or running | phase 4since Dec 19, 2012 | May 3, 2002 | Dec 30, 2032phase 3 · NCT04877288 |
| Simcere Pharmaceutical Group | 20 open or running | phase 3since Mar 10, 2016 | Mar 10, 2016 | none ahead |
| Amneal Pharmaceuticalsits history only | 10 open or running | phase 1since Jan 31, 2025 | Jan 31, 2025 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Simcere Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 10, 2016First study: phase 3 study in Arthritis, RheumatoidFirst studyNCT02722694 · 360 enrolled · China
- Jun 12, 2016Phase 1 study in Arthritis, RheumatoidNCT02805010 · 22 enrolled
TargetBeta
“T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor”ChEMBL 37, by rule
Studies
All 2 Simcere Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02805010Arthritis, Rheumatoid | 1 | UNKNOWN | Feb 2017 | 22 |
| NCT02722694Arthritis, Rheumatoid · China | 3 | UNKNOWN | Jun 2017 | 360 |
How it is read
Names in the registry
- “Abatacept”, 53 entries
- “Belatacept”, 9 entries
- “abatacept”, 4 entries
- “Abatacept (BMS-188667)”, 4 entries
- “belatacept”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 35 studies
- Arthritis, Juvenile, 3 studies
- Psoriasis, 3 studies
- Arthritis, Psoriatic, 2 studies
- Lupus Nephritis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.